Heron Therapeutics, Inc. (HRTX)

$2.6

-0.02

(-0.76%)

Market is closed - opens 8 PM, 26 Feb 2024

Insights on Heron Therapeutics, Inc.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 31.76M → 31.43M (in $), with an average decrease of 1.0% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -42.05M → -25.00M (in $), with an average increase of 68.2% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 74.3% return, outperforming this stock by 72.7%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 247.4% return, outperforming this stock by 332.7%

Performance

  • $2.55
    $2.66
    $2.60
    downward going graph

    1.92%

    Downside

    Day's Volatility :4.14%

    Upside

    2.26%

    downward going graph
  • $0.50
    $2.99
    $2.60
    downward going graph

    80.77%

    Downside

    52 Weeks Volatility :83.28%

    Upside

    13.04%

    downward going graph

Returns

PeriodHeron Therapeutics, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
89.86%
12.8%
0.0%
6 Months
53.22%
10.1%
0.0%
1 Year
1.55%
13.0%
-7.3%
3 Years
-85.33%
29.1%
-20.7%

Highlights

Market Capitalization
412.7M
Book Value
- $0.2
Earnings Per Share (EPS)
-0.88
PEG Ratio
-0.18
Wall Street Target Price
6.67
Profit Margin
-97.45%
Operating Margin TTM
-66.26%
Return On Assets TTM
-24.51%
Return On Equity TTM
-2408.88%
Revenue TTM
122.8M
Revenue Per Share TTM
0.94
Quarterly Revenue Growth YOY
18.4%
Gross Profit TTM
-50.5M
EBITDA
-95.3M
Diluted Eps TTM
-0.88
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.96
EPS Estimate Next Year
-0.43
EPS Estimate Current Quarter
-0.29
EPS Estimate Next Quarter
-0.28

Analyst Recommendation

Buy
    90%Buy
    9%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Heron Therapeutics, Inc.(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 156.54%

Current $2.60
Target $6.67

Company Financials

FY18Y/Y Change
Revenue
77.5M
↑ 151.81%
Net Income
-178.8M
↓ 9.44%
Net Profit Margin
-230.84%
↑ 411.03%
FY19Y/Y Change
Revenue
146.0M
↑ 88.41%
Net Income
-204.7M
↑ 14.49%
Net Profit Margin
-140.27%
↑ 90.57%
FY20Y/Y Change
Revenue
88.6M
↓ 39.28%
Net Income
-224.4M
↑ 9.61%
Net Profit Margin
-253.2%
↓ 112.93%
FY21Y/Y Change
Revenue
86.3M
↓ 2.59%
Net Income
-217.7M
↓ 3.02%
Net Profit Margin
-252.08%
↑ 1.12%
FY22Y/Y Change
Revenue
107.7M
↑ 24.7%
Net Income
-134.5M
↓ 38.2%
Net Profit Margin
-124.93%
↑ 127.15%
FY23Y/Y Change
Revenue
122.8M
↑ 14.09%
Net Income
-119.7M
↓ 11.01%
Net Profit Margin
-97.45%
↑ 27.48%
Q2 FY22Q/Q Change
Revenue
27.6M
↑ 17.79%
Net Income
-63.2M
↓ 2.52%
Net Profit Margin
-228.81%
↑ 47.67%
Q3 FY22Q/Q Change
Revenue
26.6M
↓ 3.88%
Net Income
-41.9M
↓ 33.67%
Net Profit Margin
-157.9%
↑ 70.91%
Q4 FY22Q/Q Change
Revenue
30.0M
↑ 13.07%
Net Income
-27.2M
↓ 35.11%
Net Profit Margin
-90.61%
↑ 67.29%
Q1 FY23Q/Q Change
Revenue
29.6M
↓ 1.38%
Net Income
-32.5M
↑ 19.35%
Net Profit Margin
-109.65%
↓ 19.04%
Q2 FY23Q/Q Change
Revenue
31.8M
↑ 7.25%
Net Income
-42.1M
↑ 29.52%
Net Profit Margin
-132.42%
↓ 22.77%
Q3 FY23Q/Q Change
Revenue
31.4M
↓ 1.03%
Net Income
-25.0M
↓ 40.54%
Net Profit Margin
-79.56%
↑ 52.86%
FY17Y/Y Change
Total Assets
234.3M
↑ 247.21%
Total Liabilities
103.2M
↑ 16.27%
FY18Y/Y Change
Total Assets
462.2M
↑ 97.25%
Total Liabilities
92.0M
↓ 10.81%
FY19Y/Y Change
Total Assets
512.8M
↑ 10.95%
Total Liabilities
108.9M
↑ 18.4%
FY20Y/Y Change
Total Assets
353.6M
↓ 31.05%
Total Liabilities
117.1M
↑ 7.45%
FY21Y/Y Change
Total Assets
305.7M
↓ 13.53%
Total Liabilities
228.1M
↑ 94.88%
FY22Y/Y Change
Total Assets
251.0M
↓ 17.91%
Total Liabilities
237.4M
↑ 4.05%
Q2 FY22Q/Q Change
Total Assets
244.0M
↓ 10.87%
Total Liabilities
265.7M
↑ 6.38%
Q3 FY22Q/Q Change
Total Assets
272.0M
↑ 11.47%
Total Liabilities
249.5M
↓ 6.1%
Q4 FY22Q/Q Change
Total Assets
251.0M
↓ 7.72%
Total Liabilities
237.4M
↓ 4.86%
Q1 FY23Q/Q Change
Total Assets
220.9M
↓ 11.98%
Total Liabilities
232.3M
↓ 2.14%
Q2 FY23Q/Q Change
Total Assets
201.2M
↓ 8.9%
Total Liabilities
240.5M
↑ 3.53%
Q3 FY23Q/Q Change
Total Assets
229.2M
↑ 13.9%
Total Liabilities
257.0M
↑ 6.85%
FY18Y/Y Change
Operating Cash Flow
-191.8M
↑ 12.63%
Investing Cash Flow
-278.6M
↓ 3699.77%
Financing Cash Flow
357.6M
↑ 21.75%
FY19Y/Y Change
Operating Cash Flow
-124.6M
↓ 35.05%
Investing Cash Flow
-21.8M
↓ 92.18%
Financing Cash Flow
186.4M
↓ 47.87%
FY20Y/Y Change
Operating Cash Flow
-184.8M
↑ 48.35%
Investing Cash Flow
209.0M
↓ 1059.26%
Financing Cash Flow
9.1M
↓ 95.12%
FY21Y/Y Change
Operating Cash Flow
-203.4M
↑ 10.03%
Investing Cash Flow
32.7M
↓ 84.34%
Financing Cash Flow
156.0M
↑ 1613.65%
FY22Y/Y Change
Operating Cash Flow
-146.9M
↓ 27.76%
Investing Cash Flow
-3.3M
↓ 110.16%
Financing Cash Flow
75.1M
↓ 51.89%
Q2 FY22Q/Q Change
Operating Cash Flow
-28.4M
↓ 35.43%
Investing Cash Flow
19.8M
↑ 80.49%
Financing Cash Flow
315.0K
↓ 149.45%
Q3 FY22Q/Q Change
Operating Cash Flow
-37.1M
↑ 30.64%
Investing Cash Flow
-36.0M
↓ 282.46%
Financing Cash Flow
74.9M
↑ 23691.11%
Q4 FY22Q/Q Change
Operating Cash Flow
-37.5M
↑ 1.26%
Investing Cash Flow
2.0M
↓ 105.61%
Financing Cash Flow
439.0K
↓ 99.41%
Q1 FY23Q/Q Change
Operating Cash Flow
-24.9M
↓ 33.66%
Investing Cash Flow
36.8M
↑ 1722.56%
Financing Cash Flow
-208.0K
↓ 147.38%
Q2 FY23Q/Q Change
Operating Cash Flow
-27.2M
↑ 9.1%
Investing Cash Flow
13.2M
↓ 64.11%
Financing Cash Flow
319.0K
↓ 253.37%
Q3 FY23Q/Q Change
Operating Cash Flow
-9.2M
↓ 66.21%
Investing Cash Flow
-23.2M
↓ 275.68%
Financing Cash Flow
53.8M
↑ 16764.26%

Technicals Summary

Sell

Neutral

Buy

Heron Therapeutics, Inc. is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Heron Therapeutics, Inc.
Heron Therapeutics, Inc.
19.09%
53.22%
1.55%
-85.33%
-90.53%
Moderna, Inc.
Moderna, Inc.
-2.43%
-13.87%
-32.62%
-33.78%
359.31%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
1.08%
14.76%
27.02%
106.16%
129.53%
Novo Nordisk A/s
Novo Nordisk A/s
18.17%
31.05%
74.29%
247.43%
403.82%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-2.94%
21.73%
45.87%
97.18%
129.05%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Heron Therapeutics, Inc.
Heron Therapeutics, Inc.
NA
NA
-0.18
-0.96
-24.09
-0.25
NA
-0.2
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-13.47
-0.22
-0.07
NA
35.32
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
27.4
27.4
1.92
44.85
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.07
46.07
4.38
3.3
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
30.21
30.21
0.57
16.74
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Heron Therapeutics, Inc.
Heron Therapeutics, Inc.
Buy
$412.7M
-90.53%
NA
-97.45%
Moderna, Inc.
Moderna, Inc.
Buy
$33.4B
359.31%
24.73
-38.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$104.6B
129.53%
27.4
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$559.6B
403.82%
46.07
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$108.4B
129.05%
30.21
36.68%

Institutional Holdings

  • Rubric Capital Management LP

    17.80%
  • Vanguard Group Inc

    5.44%
  • Baker Bros Advisors LP

    5.42%
  • BlackRock Inc

    5.42%
  • Velan Capital Investment Management LP

    4.66%
  • JPMorgan Chase & Co

    4.54%

Corporate Announcements

  • Heron Therapeutics, Inc. Earnings

    Heron Therapeutics, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

heron therapeutics, inc. (formerly a.p. pharma, inc.) is a specialty pharmaceutical company developing products using its proprietary biochronomer™ polymer-based drug delivery platform. this drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be injected only once every one or two weeks.

Organization
Heron Therapeutics, Inc.
Employees
203
CEO
Mr. Craig Alexander Collard
Industry
Health Technology

FAQs